Drug Profile
BI 135585
Alternative Names: B-135585; BI 135585 XX; BI-135585Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Vitae Pharmaceuticals
- Developer Boehringer Ingelheim
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Germany (PO, Liquid)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Germany (PO, Tablet)